Clovis Oncology, Inc.
CLVSQ
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 133.02M | 140.27M | 144.95M | 148.76M | 156.09M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 133.02M | 140.27M | 144.95M | 148.76M | 156.09M |
| Cost of Revenue | 31.59M | 32.84M | 33.26M | 33.46M | 34.54M |
| Gross Profit | 101.43M | 107.44M | 111.69M | 115.30M | 121.55M |
| SG&A Expenses | 125.53M | 127.34M | 127.67M | 128.40M | 135.81M |
| Depreciation & Amortization | 5.37M | 5.37M | 5.37M | 5.37M | 5.37M |
| Other Operating Expenses | 25.64M | 24.35M | 14.94M | 14.92M | 11.43M |
| Total Operating Expenses | 339.41M | 356.62M | 357.29M | 368.75M | 388.65M |
| Operating Income | -206.39M | -216.34M | -212.34M | -219.99M | -232.56M |
| Income Before Tax | -252.31M | -263.73M | -258.81M | -264.93M | -299.64M |
| Income Tax Expenses | -405.00K | -427.00K | -389.00K | -403.00K | -549.00K |
| Earnings from Continuing Operations | -251.91 | -263.30 | -258.42 | -264.53 | -299.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -251.91M | -263.30M | -258.42M | -264.53M | -299.09M |
| EBIT | -206.39M | -216.34M | -212.34M | -219.99M | -232.56M |
| EBITDA | -198.68M | -208.50M | -204.16M | -211.50M | -224.01M |
| EPS Basic | -1.82 | -1.99 | -2.11 | -2.31 | -2.83 |
| Normalized Basic EPS | -1.13 | -1.21 | -1.28 | -1.40 | -1.57 |
| EPS Diluted | -1.82 | -1.99 | -2.11 | -2.31 | -2.83 |
| Normalized Diluted EPS | -1.13 | -1.21 | -1.28 | -1.40 | -1.57 |
| Average Basic Shares Outstanding | 555.34M | 531.93M | 496.37M | 462.42M | 430.63M |
| Average Diluted Shares Outstanding | 555.34M | 531.93M | 496.37M | 462.42M | 430.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
